Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist.

Rose TN, Jacobs ML, Reid DJ, Bouwmeester CJ, Conley MP, Fatehi B, Matta TM, Barr JT.

J Am Pharm Assoc (2003). 2019 Oct 11. pii: S1544-3191(19)30417-0. doi: 10.1016/j.japh.2019.09.001. [Epub ahead of print]

PMID:
31611005
2.

Fraction Unbound for Liver Microsome and Hepatocyte Incubations for All Major Species Can Be Approximated Using a Single-Species Surrogate.

Barr JT, Lade JM, Tran TB, Dahal UP.

Drug Metab Dispos. 2019 Apr;47(4):419-423. doi: 10.1124/dmd.118.085936. Epub 2019 Feb 7.

PMID:
30733251
3.

Dynasore protects the ocular surface against damaging oxidative stress.

Webster A, Chintala SK, Kim J, Ngan M, Itakura T, Panjwani N, Argüeso P, Barr JT, Jeong S, Fini ME.

PLoS One. 2018 Oct 10;13(10):e0204288. doi: 10.1371/journal.pone.0204288. eCollection 2018. Erratum in: PLoS One. 2018 Dec 5;13(12):e0208864.

4.

Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results.

Yu V, Bhattacharya D, Webster A, Bauskar A, Flowers C, Heur M, Chintala SK, Itakura T, Wilson MR, Barr JT, Jeong S, Wang M, Fini ME.

Ocul Surf. 2018 Oct;16(4):478-486. doi: 10.1016/j.jtos.2018.08.001. Epub 2018 Aug 2.

5.

Eye wash water flow direction study: an evaluation of the effectiveness of eye wash devices with opposite directional water flow.

Fogt JS, Jones-Jordan LA, Barr JT.

Clin Ophthalmol. 2018 Apr 9;12:669-676. doi: 10.2147/OPTH.S157005. eCollection 2018.

6.

Scleral Lenses in the Management of Corneal Irregularity and Ocular Surface Disease.

Shorter E, Harthan J, Nau CB, Nau A, Barr JT, Hodge DO, Schornack MM.

Eye Contact Lens. 2018 Nov;44(6):372-378. doi: 10.1097/ICL.0000000000000436.

PMID:
28968300
7.

Corneal epithelial bullae after short-term wear of small diameter scleral lenses.

Nixon AD, Barr JT, VanNasdale DA.

Cont Lens Anterior Eye. 2017 Apr;40(2):116-126. doi: 10.1016/j.clae.2016.11.007. Epub 2016 Dec 16.

PMID:
27993459
8.

Tear lipid layer thickness with eye drops in meibomian gland dysfunction.

Fogt JS, Kowalski MJ, King-Smith PE, Epitropolous AT, Hendershot AJ, Lembach C, Maszczak JP, Jones-Jordan LA, Barr JT.

Clin Ophthalmol. 2016 Nov 7;10:2237-2243. eCollection 2016.

9.

Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers.

Gufford BT, Barr JT, González-Pérez V, Layton ME, White JR Jr, Oberlies NH, Paine MF.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):701-10. doi: 10.1002/psp4.12047. Epub 2015 Nov 28.

10.

A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.

Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CE, Barr JT, Jones JP, Halladay JS.

Drug Metab Dispos. 2015 Jun;43(6):908-15. doi: 10.1124/dmd.114.061804. Epub 2015 Apr 6.

11.

Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance.

Barr JT, Jones JP, Oberlies NH, Paine MF.

Drug Metab Dispos. 2015 Jan;43(1):34-41. doi: 10.1124/dmd.114.061192. Epub 2014 Oct 17.

12.

Determination of the Structure and Catalytic Mechanism of Sorghum bicolor Caffeic Acid O-Methyltransferase and the Structural Impact of Three brown midrib12 Mutations.

Green AR, Lewis KM, Barr JT, Jones JP, Lu F, Ralph J, Vermerris W, Sattler SE, Kang C.

Plant Physiol. 2014 Aug;165(4):1440-1456. Epub 2014 Jun 19.

13.

Case study 1. Practical considerations with experimental design and interpretation.

Barr JT, Flora DR, Iwuchukwu OF.

Methods Mol Biol. 2014;1113:419-29. doi: 10.1007/978-1-62703-758-7_18.

PMID:
24523122
14.

Enzyme kinetics, inhibition, and regioselectivity of aldehyde oxidase.

Barr JT, Choughule K, Jones JP.

Methods Mol Biol. 2014;1113:167-86. doi: 10.1007/978-1-62703-758-7_9. Review.

PMID:
24523113
15.

Why do most human liver cytosol preparations lack xanthine oxidase activity?

Barr JT, Choughule KV, Nepal S, Wong T, Chaudhry AS, Joswig-Jones CA, Zientek M, Strom SC, Schuetz EG, Thummel KE, Jones JP.

Drug Metab Dispos. 2014 Apr;42(4):695-9. doi: 10.1124/dmd.113.056374. Epub 2014 Jan 15.

16.

A meta-analysis of studies on cosmetically tinted soft contact lenses.

Rah MJ, Schafer J, Zhang L, Chan O, Roy L, Barr JT.

Clin Ophthalmol. 2013;7:2037-42. doi: 10.2147/OPTH.S51600. Epub 2013 Oct 11.

17.

Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography-tandem mass spectrometry.

Barr JT, Jones JP, Joswig-Jones CA, Rock DA.

Mol Pharm. 2013 Oct 7;10(10):3842-9. doi: 10.1021/mp4003046. Epub 2013 Sep 19.

18.

Evaluation of rhesus monkey and guinea pig hepatic cytosol fractions as models for human aldehyde oxidase.

Choughule KV, Barr JT, Jones JP.

Drug Metab Dispos. 2013 Oct;41(10):1852-8. doi: 10.1124/dmd.113.052985. Epub 2013 Aug 5.

19.

Potential role of cardiac calsequestrin in the lethal arrhythmic effects of cocaine.

Sanchez EJ, Hayes RP, Barr JT, Lewis KM, Webb BN, Subramanian AK, Nissen MS, Jones JP, Shelden EA, Sorg BA, Fill M, Schenk JO, Kang C.

Drug Alcohol Depend. 2013 Dec 1;133(2):344-51. doi: 10.1016/j.drugalcdep.2013.06.012. Epub 2013 Jul 19.

20.

Tear cytokine response to multipurpose solutions for contact lenses.

Kalsow CM, Reindel WT, Merchea MM, Bateman KM, Barr JT.

Clin Ophthalmol. 2013;7:1291-302. doi: 10.2147/OPTH.S44642. Epub 2013 Jun 28.

21.

Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.

Barr JT, Jones JP.

Drug Metab Dispos. 2013 Jan;41(1):24-9. doi: 10.1124/dmd.112.048546. Epub 2012 Sep 20.

22.

Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions.

Barr JT, Jones JP.

Drug Metab Dispos. 2011 Dec;39(12):2381-6. doi: 10.1124/dmd.111.041806. Epub 2011 Sep 22.

23.

Myopia progression during three years of soft contact lens wear.

Blacker A, Mitchell GL, Bullimore MA, Long B, Barr JT, Dillehay SM, Bergenske P, Donshik P, Secor G, Yoakum J, Chalmers RL.

Optom Vis Sci. 2009 Oct;86(10):1150-3. doi: 10.1097/OPX.0b013e3181bab365.

24.

Clinical relevance of the superficial corneal surface fluorescence phenomenon.

Barr JT, Snyder C.

Optometry. 2009 Mar;80(3):116-7; author reply 117-8. doi: 10.1016/j.optm.2009.01.002. No abstract available.

PMID:
19264285
25.

Higher-order aberrations when wearing sphere and toric soft contact lenses.

Berntsen DA, Merchea MM, Richdale K, Mack CJ, Barr JT.

Optom Vis Sci. 2009 Feb;86(2):115-22. doi: 10.1097/OPX.0b013e318194e951.

26.

Fluorescein pattern interpretation in keratoconus.

Fink B, Heard C, Schafer J, Cline AR, Mitchell L, Barr JT.

Optom Vis Sci. 2008 Oct;85(10):E939-46. doi: 10.1097/OPX.0b013e3181886fb6.

PMID:
18832969
27.

Visual acuity with spherical and toric soft contact lenses in low- to moderate-astigmatic eyes.

Richdale K, Berntsen DA, Mack CJ, Merchea MM, Barr JT.

Optom Vis Sci. 2007 Oct;84(10):969-75.

PMID:
18049362
28.

Inflammatory and mechanical complications associated with 3 years of up to 30 nights of continuous wear of lotrafilcon A silicone hydrogel lenses.

Donshik P, Long B, Dillehay SM, Bergenske P, Barr JT, Secor G, Yoakum J, Chalmers RL.

Eye Contact Lens. 2007 Jul;33(4):191-5.

PMID:
17630627
29.

Long-term clinical results: 3 years of up to 30-night continuous wear of lotrafilcon A silicone hydrogel and daily wear of low-Dk/t hydrogel lenses.

Bergenske P, Long B, Dillehay S, Barr JT, Donshik P, Secor G, Yoakum J, Chalmers RL.

Eye Contact Lens. 2007 Mar;33(2):74-80.

PMID:
17496699
30.

Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: methods and findings to date.

Wagner H, Barr JT, Zadnik K.

Cont Lens Anterior Eye. 2007 Sep;30(4):223-32. Epub 2007 May 3.

31.

A new method for grading the severity of keratoconus: the Keratoconus Severity Score (KSS).

McMahon TT, Szczotka-Flynn L, Barr JT, Anderson RJ, Slaughter ME, Lass JH, Iyengar SK; CLEK Study Group.

Cornea. 2006 Aug;25(7):794-800.

PMID:
17068456
32.

The effect of overnight contact lens corneal reshaping on refractive error-specific quality of life.

Berntsen DA, Mitchell GL, Barr JT.

Optom Vis Sci. 2006 Jun;83(6):354-9.

PMID:
16772893
33.

Comparison of flat and steep rigid contact lens fitting methods in keratoconus.

Zadnik K, Barr JT, Steger-May K, Edrington TB, McMahon TT, Gordon MO; Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group.

Optom Vis Sci. 2005 Dec;82(12):1014-21.

PMID:
16357642
34.

Estimation of the incidence and factors predictive of corneal scarring in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study.

Barr JT, Wilson BS, Gordon MO, Rah MJ, Riley C, Kollbaum PS, Zadnik K; CLEK Study Group.

Cornea. 2006 Jan;25(1):16-25.

PMID:
16331035
35.

The current state of corneal reshaping.

Walline JJ, Holden BA, Bullimore MA, Rah MJ, Asbell PA, Barr JT, Caroline PJ, Cavanagh HD, Despotidis N, Desmond F, Koffler BH, Reeder K, Swarbrick HA, Wohl LG.

Eye Contact Lens. 2005 Sep;31(5):209-14. Review.

PMID:
16163012
36.

Impact of previous extended and daily wear schedules on signs and symptoms with high Dk lotrafilcon A lenses.

Chalmers RL, Dillehay S, Long B, Barr JT, Bergenske P, Donshik P, Secor G, Yoakum J.

Optom Vis Sci. 2005 Jun;82(6):549-54.

PMID:
15976593
37.
38.

The comparison of overnight lens modalities (COLM) study.

Ritchey ER, Barr JT, Mitchell GL.

Eye Contact Lens. 2005 Mar;31(2):70-5.

PMID:
15798477
39.

Linking variation in the structure and process of bedside glucose testing programs with patient outcomes.

Barr JT, Otto CN, Freeman SF, Barrett C, Hirsch CA, Cerda SR.

Clin Lab Sci. 2001 Winter;14(1):27-32.

PMID:
15633491
40.

Recovery of refractive error after corneal refractive therapy.

Barr JT, Rah MJ, Meyers W, Legerton J.

Eye Contact Lens. 2004 Oct;30(4):247-51; discussion 263-4.

PMID:
15499264
41.

Variables affecting rigid contact lens comfort in the collaborative longitudinal evaluation of keratoconus (CLEK) study.

Edrington TB, Gundel RE, Libassi DP, Wagner H, Pierce GE, Walline JJ, Barr JT, Olafsson HE, Steger-May K, Achtenberg J, Wilson BS, Gordon MO, Zadnik K; CLEK STUDY GROUP.

Optom Vis Sci. 2004 Mar;81(3):182-8.

PMID:
15017177
42.

Orthokeratology and corneal refractive therapy: a review and recent findings.

Barr JT, Rah MJ, Jackson JM, Jones LA.

Eye Contact Lens. 2003 Jan;29(1 Suppl):S49-53; discussion S57-9, S192-4. Review.

PMID:
12772731
43.

Corneal endothelial morphology results in the Menicon Z 30-day continuous-wear contact lens clinical trial.

Barr JT, Pall B, Szczotka LB, Mitchell GL, Gleason W.

Eye Contact Lens. 2003 Jan;29(1):14-6.

PMID:
12769149
44.

Corneal thickness results in the Menicon Z 30-day continuous wear and ACUVUE 7-day extended-wear contact lens clinical trial.

Pall B, Barr JT, Szczotka LB, Mitchell GL, Gleason W.

Eye Contact Lens. 2003 Jan;29(1):10-3.

PMID:
12769148
45.

The need for a nutrition-related quality-of-life measure.

Barr JT, Schumacher GE.

J Am Diet Assoc. 2003 Feb;103(2):177-80. No abstract available.

PMID:
12589322
46.

Therapeutic drug monitoring: is it cost-effective?

Schumacherand GE, Barr JT.

Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):619-24. doi: 10.1586/14737167.2.6.619.

PMID:
19807486
47.

Corneal pigmentation in overnight orthokeratology: a case series.

Rah MJ, Barr JT, Bailey MD.

Optometry. 2002 Jul;73(7):425-34. Review.

PMID:
12365661
48.

Overnight orthokeratology: preliminary results of the Lenses and Overnight Orthokeratology (LOOK) study.

Rah MJ, Jackson JM, Jones LA, Marsden HJ, Bailey MD, Barr JT.

Optom Vis Sci. 2002 Sep;79(9):598-605.

PMID:
12322930
49.
50.

Case problem: quality of life outcomes assessment. How can you use it in medical nutrition therapy?

Barr JT, Schumacher G, Myers EF.

J Am Diet Assoc. 2001 Sep;101(9):1064-6. No abstract available.

PMID:
11573763

Supplemental Content

Support Center